Results 1 to 10 of about 440,184 (328)

Peripheral T-cell lymphoma, not otherwise specified [PDF]

Journal of Family Medicine and Primary Care, 2017
The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct ...
Kunal Kishor Jha, Suresh K Gupta, Harpreet Saluja, Nuwadatta Subedi   +3 more
doaj   +9 more sources

Therapeutic options in peripheral T cell lymphoma [PDF]

Journal of Hematology & Oncology, 2016
Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes.
Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li   +3 more
doaj   +5 more sources

Genetic Landscape of Peripheral T-Cell Lymphoma

Life, 2022
Peripheral T-Cell lymphoma (PTCL) comprises a heterogenous group of uncommon lymphomas derived from mature, post-thymic or “peripheral” T- and natural killer cells. The World Health Organization (WHO) emphasizes a multiparameter approach in the diagnosis
Vivian Hathuc, Friederike Kreisel
doaj   +3 more sources

Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas [PDF]

Haematologica, 2013
Peripheral T-cell lymphomas are very aggressive hematologic malignancies for which there is no targeted therapy. New, rational approaches are necessary to improve the very poor outcome in these patients.
Esperanza Martín-Sánchez, Socorro M. Rodríguez-Pinilla, Margarita Sánchez-Beato, Luis Lombardía, Beatriz Domínguez-González, Diana Romero, Lina Odqvist, Pablo García-Sanz, Magdalena B. Wozniak, Guido Kurz, Carmen Blanco-Aparicio, Manuela Mollejo, F. Javier Alves, Javier Menárguez, Fernando González-Palacios, José Luis Rodríguez-Peralto, Pablo L. Ortiz-Romero, Juan F. García, James R. Bischoff, Miguel A. Piris   +19 more
doaj   +3 more sources

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study [PDF]

eJHaem
Objective We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed/ refractory T‐cell lymphoma. Methods A dose escalation study design was utilized.
Carrie van der Weyden, Mathias Bressel, Amit Khot, Henry Miles Prince, Michael Dickinson   +4 more
doaj   +2 more sources

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

Haematologica, 2018
Due to heterogeneous morphological and immunophenotypic features, approximately 50% of peripheral T-cell lymphomas are unclassifiable and categorized as peripheral T-cell lymphomas, not otherwise specified.
Meng-Meng Ji, Yao-Hui Huang, Jin-Yan Huang, Zhao-Fu Wang, Di Fu, Han Liu, Feng Liu, Christophe Leboeuf, Li Wang, Jing Ye, Yi-Ming Lu, Anne Janin, Shu Cheng, Wei-Li Zhao   +13 more
doaj   +2 more sources

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma

JAMA Network Open, 2021
Key Points Question Is allogeneic hematopoietic stem cell transplant (HSCT) or autologous HSCT more effective and safer for patients with refractory or relapsed peripheral T-cell lymphoma? Findings In this systematic review and meta-analysis of 30 trials
Jun Du, Dandan Yu, Xin-le Han, Lijun Zhu, Zoufang Huang   +4 more
semanticscholar   +1 more source

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas

Experimental Hematology & Oncology, 2021
Background The 2016 World Health Organization (WHO) classification introduced nodal lymphomas of T follicular helper (Tfh) cell origin, such as angioimmunoblastic T-cell lymphoma (AITL), follicular peripheral T-cell lymphoma (F-PTCL), and nodal ...
Sang Eun Yoon, Junhun Cho, Yeon Jeong Kim, Young Hyeh Ko, Woong-Yang Park, Seok Jin Kim, Won Seog Kim   +6 more
doaj   +1 more source

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.

Blood Advances, 2020
Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma (PTCL). Anecdotally angioimmunoblastic T-cell lymphoma (AITL) appears to respond better than PTCL-not otherwise specified (NOS) to HDACi.
P. Ghione, Promie Faruque, N. Mehta-Shah, V. Seshan, N. Ozkaya, Shakthi T Bhaskar, J. Yeung, Michael A. Spinner, M. Lunning, G. Inghirami, A. Moskowitz, N. Galasso, N. Ganesan, Carrie van der Weyden, J. Ruan, H. Prince, J. Trotman, R. Advani, A. Dogan, S. Horwitz   +19 more
semanticscholar   +1 more source

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Clinical Epigenetics, 2020
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of clinically aggressive diseases associated with poor prognosis. Except for ALK + anaplastic large-cell lymphoma (ALCL), most peripheral T-cell lymphomas are highly malignant and have ...
Ping Zhang, Mingzhi Zhang
semanticscholar   +1 more source